Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer.

Summary: For patients with endometrial cancer that has returned after initial treatment, doctors are finding new hope in a combination of two drugs: nivolumab (an immunotherapy) and cabozantinib (a targeted therapy). A recent clinical trial showed that using these two drugs together works better than using immunotherapy alone. However, not every patient responds the same way. By analyzing blood samples, researchers discovered specific "fingerprints" in the immune system. Patients with active T-cells (the soldiers of the immune system) tended to live longer and respond better. Conversely, patients with high levels of specific inflammation markers (myeloid cells) had a harder time fighting the cancer. This discovery is a crucial step toward personalized medicine, helping doctors predict who will benefit most and how to design better treatments for those who might resist the current drugs.